Academic Journal
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
| العنوان: | Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial |
|---|---|
| المؤلفون: | Llombart-Cussac, Antonio, Prat, Aleix, Pérez-García, José Manuel, Mateos, José, Pascual, Tomás, Escrivá-de-Romani, Santiago, Stradella, Agostina, Ruiz Borrego, Manuel, de las Heras, Begoña, Keyaerts, Marleen, Galvan, Patricia, Brasó-Maristany, Fara, García-Mosquera, Juan José, Guiot, Thomas, Gion, María, Sampayo-Cordero, Miguel, Di Cosimo, Serena, Pérez-Escuredo, Jhudit, de Frutos, Manuel Atienza, Cortes, Javier, Gebhart, Géraldine |
| المصدر: | European journal of nuclear medicine and molecular imaging |
| سنة النشر: | 2024 |
| المجموعة: | DI-fusion : dépôt institutionnel de l'Université libre de Bruxelles (ULB) |
| مصطلحات موضوعية: | Imagerie médicale, radiologie, tomographie, Disease detection, Early breast cancer, HER2-positive, Predictors, [18F]FDG-PET |
| الوصف: | Background: The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [18Fluorine]fluorodeoxyglucose-positron emission tomography ([18F]FDG-PET) and a pathological complete response-adapted strategy in HER2-positive (HER2+) early breast cancer (EBC). Herein, we present RESPONSE, a PHERGain substudy, where clinicopathological and molecular predictors of [18F]FDG-PET disease detection were evaluated. Methods: A total of 500 patients with HER2 + EBC screened in the PHERGain trial with a tumor size > 1.5 cm by magnetic resonance imaging (MRI) were included in the RESPONSE substudy. PET[−] criteria entailed the absence of ≥ 1 breast lesion with maximum standardized uptake value (SUVmax) ≥ 1.5 × SUVmean liver + 2 standard deviation. Among 75 PET[−] patients screened, 21 with SUVmax levels < 2.5 were randomly selected and matched with 21 PET[+] patients with SUVmax levels ≥ 2.5 based on patient characteristics associated with [18F]FDG-PET status. The association between baseline SUVmax and [18F]FDG-PET status ([−] or [+]) with clinicopathological characteristics was assessed. In addition, evaluation of stromal tumor-infiltrating lymphocytes (sTILs) and gene expression analysis using PAM50 and Vantage 3D™ Cancer Metabolism Panel were specifically compared in a matched cohort of excluded and enrolled patients based on the [18F]FDG-PET eligibility criteria. Results: Median SUVmax at baseline was 7.2 (range, 1–39.3). Among all analyzed patients, a higher SUVmax was associated with a higher tumor stage, larger tumor size, lymph node involvement, hormone receptor-negative status, higher HER2 protein expression, increased Ki67 proliferation index, and higher histological grade (p < 0.05). [18F]FDG-PET [−] criteria patients had smaller tumor size (p = 0.014) along with the absence of lymph node involvement and lower histological grade than [18F]FDG-PET [+] patients (p < 0.01). Although no difference in the ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 1 full-text file(s): application/pdf |
| اللغة: | English |
| Relation: | uri/info:doi/10.1007/s00259-024-06683-0; uri/info:scp/85189686448; https://dipot.ulb.ac.be/dspace/bitstream/2013/373778/1/doi_357422.pdf; http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/373778 |
| الاتاحة: | http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/373778 https://dipot.ulb.ac.be/dspace/bitstream/2013/373778/1/doi_357422.pdf |
| رقم الانضمام: | edsbas.F97D031A |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |